Apollomics Inc. Class A Ordinary Shares (APLM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Apollomics Inc. Class A Ordinary Shares stock (APLM) is currently trading at $17.54. Apollomics Inc. Class A Ordinary Shares PS ratio (Price-to-Sales) is 5.73. Analyst consensus price target for APLM is $2.00. WallStSmart rates APLM as Sell.
- APLM PE ratio analysis and historical PE chart
- APLM PS ratio (Price-to-Sales) history and trend
- APLM intrinsic value — DCF, Graham Number, EPV models
- APLM stock price prediction 2025 2026 2027 2028 2029 2030
- APLM fair value vs current price
- APLM insider transactions and insider buying
- Is APLM undervalued or overvalued?
- Apollomics Inc. Class A Ordinary Shares financial analysis — revenue, earnings, cash flow
- APLM Piotroski F-Score and Altman Z-Score
- APLM analyst price target and Smart Rating
Apollomics Inc. Class A
📊 No data available
Try selecting a different time range
Smart Analysis
Apollomics Inc. Class A Ordinary Shares (APLM) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Apollomics Inc. Class A Ordinary Shares (APLM) Key Strengths (2)
Keeps $1007 of every $100 in revenue after operating costs
Revenue surging 262.30% year-over-year
Apollomics Inc. Class A Ordinary Shares (APLM) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 8.2x book value
Very low institutional interest at 0.67%
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 5.7x annual revenue
Supporting Valuation Data
Apollomics Inc. Class A Ordinary Shares (APLM) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Revenue Growth. Profitability is solid with Operating Margin at 1007.00%. Growth metrics are encouraging with Revenue Growth at 262.30%.
The Bear Case
The primary concerns are Return on Equity, Price/Book, Institutional Own.. Some valuation metrics including Price/Sales (5.73), Price/Book (8.15) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -233.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -233.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 262.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
APLM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
APLM's Price-to-Sales ratio of 5.73x trades at a deep discount to its historical average of 52.51x (25th percentile). The current valuation is 97% below its historical high of 218.77x set in Feb 2026, and 1748% above its historical low of 0.31x in Aug 2024. Over the past 12 months, the PS ratio has compressed from ~82.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Apollomics Inc. Class A Ordinary Shares (APLM) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Apollomics Inc. Class A Ordinary Shares is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 198,000 with 262% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 262% YoY, reaching 198,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of -0.17 indicates a conservative balance sheet with 2M in cash.
Free cash flow is -13M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Apollomics Inc. Class A Ordinary Shares maintain 262%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.81, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Apollomics Inc. Class A Ordinary Shares.
Bottom Line
Apollomics Inc. Class A Ordinary Shares is a high-conviction growth story with revenue accelerating at 262% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Apollomics Inc. Class A Ordinary Shares(APLM)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company is headquartered in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.